Philadelphia, Pennsylvania--(Newsfile Corp. - February 5, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company") on behalf of investors who purchased American Depositary Shares ("ADS") issued by Mereo during the period from June 5, 2023 through December 26, 2025 (the "Class Period").Investor Deadline: Investors who purchased Mereo securities during the Class Period may, no late ...

Core Insights - Verastem's shares increased nearly 8% following the announcement of preliminary sales figures for Q4 and FY2025 [1][6] - The company reported expected net product revenues of approximately $17.5 million for Q4 2025 and $30.9 million for the full year 2025, attributed to the U.S. launch of Avmapki Fakzynja Co-pack after FDA approval in May 2025 [2][6] - Verastem ended 2025 with around $205 million in cash and investments, projecting a cash runway into the first half of 2027 [3][6] Financial Performance - Preliminary net product revenues for Q4 2025 are expected to be approximately $17.5 million, while full-year revenues are projected at $30.9 million [2][6] - The company raised $29.4 million through the exercise of outstanding cash warrants by January 25, 2026 [2] Market Position and Growth - Verastem anticipates that the LGSOC commercial launch and development program will become self-sustaining by the second half of 2026, driven by strong sales growth [3][6] - Over the past year, Verastem's shares have increased by 11.4%, compared to a 32.7% rise in the industry [3] Pipeline Developments - The company is focusing on maximizing value from the Avmapki Fakzynja Co-pack launch while advancing a pipeline targeting RAS/MAPK pathway-driven cancers [7] - Avmapki Fakzynja Co-pack is currently being evaluated in the phase III RAMP 301 study, with top-line data expected in mid-2027 [7] - In Japan, the combination drug is being assessed in the mid-stage RAMP201J study, showing a 38% overall response rate, including 57% in KRAS-mutated patients [8] Future Plans - Verastem plans to select the recommended phase II dose in combination with Erbitux (cetuximab) and initiate expansion studies in colorectal cancer in the first half of 2026 [10] - The company aims to report interim data from the phase I/II study of VS-7375 in the first half of 2026 [9] - Updated data on the RAMP 205 study, evaluating avutometinib plus defactinib, is expected in the second quarter of 2026 [11]

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of American Depositary Shares ("ADS†) of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023, and December 26, 2025. Mereo describes itself as a "biopharmaceutical company focused on the development of therapeutics for rare diseases.†For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Ro. ...

This Medical Technology Leader Sees Growth Into The 2040s | Investor's Business DailySPECIAL REPORT: [Find The Online Broker That Best Fits Your Needs]---Medical technology leader Halozyme Therapeutics (HALO) is this week's IBD Sector Leaders selection, having bypassed two buy points and entered a buy zone. The recent IBD Stock Of The Day is rallying after the company raised its 2025 and 2026 outlook. It also offered a bold forecast for 2027, 2028 and beyond. The biopharmaceutical company's enzyme technolog ...

Core Insights - Longeveron Inc. supports the passing of the Mikaela Naylon Give Kids a Chance Act, which reauthorizes the Rare Pediatric Disease Priority Review Voucher Program, incentivizing the development of treatments for rare pediatric diseases [2][3]. Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions [2][9]. - The company's lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell therapy aimed at addressing unmet medical needs in various disease areas, including Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease, and Pediatric Dilated Cardiomyopathy [9]. Legislative Impact - The Mikaela Naylon Give Kids a Chance Act allows companies to receive a priority review voucher upon FDA approval of a therapy for rare pediatric diseases, which can be used for expedited review of future therapies or sold [3][8]. - Since August 2024, these vouchers have been sold for $150-200 million each, with over 60 vouchers awarded for 40 pediatric diseases since the program's inception [3]. Clinical Development - Longeveron is currently conducting the ELPIS II Phase 2b clinical trial for laromestrocel in children with HLHS, enrolling 40 pediatric patients across twelve leading treatment institutions [5]. - Top-line results from the ELPIS II trial are expected in the third quarter of 2026, and if positive, the company plans to submit a Biological License Application (BLA) for full approval [5]. Unmet Medical Need - HLHS is a severe congenital heart defect with a high mortality rate, where only 50% of affected infants survive to adolescence despite current treatment options [4][6]. - There is a significant unmet medical need to improve right ventricular function in HLHS patients to enhance both short-term and long-term outcomes [6].

Core Viewpoint - GRI Bio, Inc. is participating in the Corporate Connect Webinar Series hosted by Webull Financial on February 10-11, 2026, to discuss its innovative pipeline of immune cell modulators for treating inflammatory, fibrotic, and autoimmune diseases [1][2]. Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on transforming the treatment of inflammatory, fibrotic, and autoimmune diseases through therapies targeting Natural Killer T (NKT) cells [3]. - The company's lead program, GRI-0621, is an RARβγ agonist aimed at inhibiting iNKT cell activity and is being developed as an oral therapeutic for idiopathic pulmonary fibrosis, a disease with significant unmet needs [3]. - GRI Bio is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds to support its growing pipeline [3]. Webinar Details - The presentation will take place on February 11, 2026, at 1:00 PM EST, led by Marc Hertz, PhD, the President and CEO of GRI Bio [2].

Company Overview - Decoy Therapeutics, Inc. is a preclinical-stage biotechnology company focused on developing peptide conjugate therapeutics targeting serious unmet medical needs, particularly in respiratory viruses and gastrointestinal cancers [3] - The company utilizes machine learning and artificial intelligence tools alongside high-speed synthesis techniques to design and manufacture its drug candidates [3] - Decoy has secured financing from institutional investors and non-dilutive capital sources, including the Massachusetts Life Sciences Seed Fund, Google AI startup program, and NVIDIA Inception program [3] Upcoming Presentation - Decoy Therapeutics will participate in the Corporate Connect Webinar Series hosted by Webull Financial on February 10-11, 2026 [1] - Rick Pierce, the CEO of Decoy Therapeutics, will provide a corporate overview and discuss a new class of antiviral therapeutics capable of targeting multiple viral pathogens with a single drug [2] Financial and Strategic Partnerships - The company has received funding from the Biomedical Advanced Research and Development Authority (BARDA) through the QuickFire Challenge award, in collaboration with Johnson & Johnson Innovation – JLABS [3]

Core Viewpoint - Palisade Bio, Inc. is advancing its clinical-stage biopharmaceutical product, PALI-2108, a once-daily oral PDE4 inhibitor prodrug aimed at treating inflammatory and fibrotic diseases, with a focus on targeted delivery to the terminal ileum and colon [2][6]. Group 1: Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing next-generation oral PDE4 inhibitor prodrugs to enhance pharmacology, tolerability, and convenience for patients [6]. - The company is committed to transforming established PDE4 biology into safer oral therapies for chronic inflammatory and fibrotic diseases through its differentiated prodrug platform [6]. Group 2: Product Details - PALI-2108 is designed for targeted delivery of PDE4 inhibition to the terminal ileum and colon, activated by local bacterial bioactivation, which minimizes systemic absorption and improves tolerability [5]. - In a Phase 1b trial, PALI-2108 demonstrated a 100% clinical response in the ulcerative colitis (UC) cohort, with no serious adverse events and favorable pharmacokinetics [7]. Group 3: Clinical Development - The company is progressing towards a Phase 2 clinical study in UC, which will evaluate clinical remission, response, and pharmacodynamic biomarkers over a 12-week period, including an extension phase for maintenance of remission [8]. - Early studies are being completed in fibrotic diseases to further assess PALI-2108's safety, pharmacology, and potential therapeutic benefits across inflammatory bowel disease indications [8].

Core Viewpoint - Propanc Biopharma, Inc. is advancing its lead proenzyme therapy, PRP, as a novel treatment for chronic diseases, particularly targeting solid tumors with high unmet needs like pancreatic cancer [1][5]. Company Overview - Propanc Biopharma, Inc. focuses on developing innovative treatments aimed at preventing cancer recurrence and metastasis by targeting cancer stem cells through proenzyme activation [10]. - The company has received FDA Orphan Drug Designation for PRP in pancreatic cancer, highlighting its potential in a critical treatment gap [5]. Product Details - PRP is an intravenous formulation combining two pancreatic proenzymes, trypsinogen and chymotrypsinogen, designed to inhibit tumor growth and enhance chemosensitivity, showing over 85% tumor growth inhibition in preclinical studies [2][3]. - The therapy aims to address the root causes of cancer proliferation and metastasis, offering a potentially less toxic alternative to existing therapies [3]. Market Opportunity - The global pancreatic cancer treatment market was valued at approximately $3.25 billion in 2025 and is projected to reach $3.70 billion in 2026, with significant growth expected to $10.25 billion by 2034, reflecting a CAGR of 13.62% [6]. - Solid tumors, including pancreatic, ovarian, and colorectal cancers, account for about 80% of all cancers, representing a substantial commercial opportunity for Propanc [7]. Clinical Development - Propanc is preparing for a Phase 1b First-In-Human study in 2026, targeting approximately 30-40 patients with advanced solid tumors, which will inform subsequent Phase 2 studies [8]. - The company is enhancing its intellectual property portfolio with recent provisional patent filings to protect its formulations and therapeutic applications [8]. Strategic Vision - The CEO of Propanc expressed optimism about PRP's potential to transform cancer care by targeting the mechanisms of metastasis, aiming to provide hope to patients with limited treatment options [9].

Core Insights - Polaryx Therapeutics, Inc. has appointed three new members to its Board of Directors, enhancing its expertise in scientific research, clinical development, finance, and corporate strategy as it progresses as a public company [1][2][3] Board Appointments - Mitchel Berger, M.D., Francis A. Braun III, CPA, and Charles Ryan, J.D., Ph.D. have been appointed to the Board, effective January 29, 2026, while Andrew O has ceased to serve [1][2] - The new board members bring extensive experience: Dr. Berger is a prominent figure in neuro-oncology, Mr. Braun has a strong background in finance and advisory roles, and Dr. Ryan has significant experience in biotechnology and regulatory affairs [3][4][5][6] Company Milestones - Polaryx is advancing its lead candidate, PLX-200, into an IND-approved SOTERIA Phase 2 basket trial, marking a significant near-term milestone for the company [2][3] - The company focuses on developing therapies for rare, pediatric lysosomal storage disorders (LSDs), aiming to address significant unmet medical needs [7]